APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer

Molecular Cancer Therapeutics

Volumn 16, Issue 4, 2017, Pages 752-762

  Tanaka, Noritaka ^a,b   Mashima, Tetsuo ^a   Mizutani, Anna ^a   Sato, Ayana ^a,c   Aoyama, Aki ^a,c   Gong, Bo ^a,c   Yoshida, Haruka ^a   Muramatsu, Yukiko ^a   Nakata, Kento ^a,d   Matsuura, Masaaki ^e   Katayama, Ryohei ^a   Nagayama, Satoshi ^f   Fujita, Naoya ^a,c,d   Sugimoto, Yoshikazu ^b   Seimiya, Hiroyuki ^a,c,d  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; CASEIN KINASE IALPHA; TANKYRASE INHIBITOR; TUMOR MARKER; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; APC PROTEIN, HUMAN; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; G007-LK; IMIDE; IWR-1 COMPOUND; PROTEIN BINDING; QUINOLINE DERIVATIVE; SULFONE; TANKYRASE; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ECTOPIC EXPRESSION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; BINDING SITES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HT29 CELLS; HUMANS; IMIDES; PROTEIN BINDING; QUINOLINES; SULFONES; TANKYRASES; TRIAZOLES; WNT SIGNALING PATHWAY;

EID: 85016947218     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0578     Document Type: Article

References (44)

1. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
2. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2002;1:55-67.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
4. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
5. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996;272:1023-6.
6. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998;8: 573-81.
7. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998;280:596-9.
8. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of betacatenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-47.
9. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E,MannM, et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002;16:1066-76.
10. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 2012;149:1245-56.
11. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010;107:1565-70.
12. Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 2015;161:1539-52.
13. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998;282:1484-7.
14. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br J Cancer 2006;94:341-5.
15. Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 2012;11: 923-36.
16. Seimiya H, Muramatsu Y, Smith S, Tsuruo T. Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation. Mol Cell Biol 2004;24:1944-55.
17. Seimiya H, Smith S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). J Biol Chem 2002;277:14116-26.
18. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
19. Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol 2011;13:623-9.
20. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small moleculemediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
21. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012;72:2822-32.
22. Lau T, Chan E, CallowM, Waaler J, Boggs J, Blake RA, et al.Anovel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 2013;73:3132-44.
23. Okada-Iwasaki R, Takahashi Y, Watanabe Y, Ishida H, Saito J, Nakai R, et al. The discovery and characterization of K-756, a novel Wnt/betacatenin pathway inhibitor targeting tankyrase. Mol Cancer Ther 2016; 15:1525-34.
24. Mashima T, Oh-hara T, Sato S, Mochizuki M, Sugimoto Y, Yamazaki K, et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005;97:765-77.
25. Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, et al. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. Int J Cancer 2014; 135:37-47.
26. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-21.
27. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/betacatenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002;22:1172-83.
28. YanD,WiesmannM, RohanM, Chan V, Jefferson AB, Guo L, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A 2001;98:14973-8.
29. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ, et al. The 'just-right' signalingmodel: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 2002;11:1549-60.
30. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98.
31. Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F, et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene 2013;32:4675-82.
32. Schmieder R, Hoffmann J, Becker M, Bhargava A, Muller T, Kahmann N, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 2013;135: 1487-96.
33. Green RA, Wollman R, Kaplan KB. APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment. Mol Biol Cell 2005;16:4609-22.
34. Su LK, Burrell M, Hill DE, Gyuris J, Brent R,Wiltshire R, et al. APC binds to the novel protein EB1. Cancer Res 1995;55:2972-7.
35. Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003;1:E10.
36. Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with betacatenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 1998;3:395-403.
37. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000;1:519-23.
38. Rosin-Arbesfeld R, Townsley F, BienzM. The APC tumour suppressor has a nuclear export function. Nature 2000;406:1009-12.
39. Croy HE, Fuller CN, Giannotti J, Robinson P, Foley AV, Yamulla RJ, et al. The Poly(ADP-ribose) polymerase enzyme tankyrase antagonizes activity of the beta-catenin destruction complex through ADP-ribosylation of axin and APC2. J Biol Chem 2016;291:12747-60.
40. Martino-Echarri E, Brocardo MG, Mills KM, Henderson BR. Tankyrase inhibitors stimulate the ability of tankyrases to bind axin and drive assembly of b-catenin degradation-competent axin puncta. PLoS One 2016;11:e0150484.
41. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directedmolecular cancer therapeutics. Cancer Cell 2005;7:25-37.
42. Dynek JN, Smith S. Resolution of sister telomere association is required for progression through mitosis. Science 2004;304:97-100.
43. Li N, Zhang Y, Han X, Liang K, Wang J, Feng L, et al. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev 2014;29:157-70.
44. Wang W, Li N, Li X, Tran MK, Han X, Chen J. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep 2015;13:524-32.